Proceedings of Anticancer Research

Application of Proteomic and Metabolomic Technologies in Renal Cell Carcinoma and Research Progress of Related Biomarkers

2025-05-29T15:41:48+08:00

Renal cell carcinoma (RCC), which accounts for about 90 percent of kidney cancers, has a distinct metabolic reprogramming profile characterized by increased aerobic glycolysis (Warburg effect), abnormal accumulation of lipids, and impaired mitochondrial function. Recent advances in high-throughput proteomic and metabolomic technologies have revolutionized our understanding of the pathophysiology of RCC, allowing for the systematic identification of disease-specific molecular signatures, elucidation of drug resistance mechanisms, and possible targets for intervention. The review focuses on the use of proteomic and metabolomic technologies in renal cell carcinoma and the research progress on related biomarkers, and is expected to provide useful information for the early detection and treatment of RCC.

LINC00936 Suppresses Non-Small Cell Lung Cancer Progression Through Modulation of the Ras/MAPK Signaling Pathway

2025-05-29T15:41:50+08:00

Objective: To characterize the tumor-suppressive role of LINC00936 in non-small cell lung cancer (NSCLC) through mechanistic exploration of its regulatory pathways. Methods: Bioinformatics interrogation of TCGA/NSCLC cohorts assessed LINC00936 expression, clinical correlations, and immune contexture. Functional enrichment analyses predicted pathway associations. In H1299 cells, LINC00936 overexpression (plasmid) and knockdown (siRNA) models were validated by RT-qPCR. Transcriptomic profiling identified differentially expressed genes (DEGs) subjected to KEGG pathway analysis. Results: LINC00936 was significantly downregulated in NSCLC tissues (TCGA, P < 0.05) and cell lines (vs. 16-HBE, P < 0.05), correlating with poor prognosis and altered tumor-infiltrating immune subsets. DEG enrichment implicated Ras/MAPK signaling as the dominant pathway (FDR < 0.05). Successful LINC00936 modulation (overexpression/knockdown, P < 0.05) confirmed its regulatory capacity. Conclusion: LINC00936 acts as a tumor suppressor in NSCLC via Ras/MAPK pathway modulation, proposing its therapeutic candidacy for precision oncology strategies.

Risk Assessment Models for Venous Thromboembolism in Gynecological Patients: A Review of Current Practices and Future Directions

2025-05-29T15:41:46+08:00

This article introduces and compares risk assessment models for venous thromboembolism in gynecological patients at home and abroad. The models assessed included the Caprini risk assessment model, the G-Caprini risk assessment model, the Rogers risk assessment model, the Autar risk assessment model, the gynecological patient surgical venous thrombosis risk assessment scale, the Wells score, the COMPASS-CAT thrombus risk assessment model, the Khorana risk assessment model, the Padua risk assessment model, and the Chaoyang model. The purpose of this study is to provide a foundation for developing a risk assessment tool for gynecological venous thromboembolism tailored to Chinese patients and to assist clinical health care workers in selecting appropriate risk assessment tools and guiding individualized prevention measures.

HSP70 is the Most Significantly Upregulated Molecule Upon Bortezomib Stimulation: A Study Based on the Multiple Myeloma Database

2025-06-05T13:01:47+08:00

Objective: This study aimed to investigate the changes in gene expression profiles of multiple myeloma (MM) cells after bortezomib treatment by analyzing the GEO database, thereby providing a theoretical foundation for subsequent research on HSP70. Methods: The GSE41929 dataset was selected from the GEO database. Screening and analysis were performed to identify differentially expressed genes between bortezomib-treated and non-treated MM cells. Results: After bortezomib treatment, 126 genes in MM cells showed the most significant changes in expression (P < 0.05, absolute value of logFC ≥ 1.5). Based on the fold change and the most significant gene module, HSPA1B exhibited the most notable upregulation after HMOX1, followed by HSPA6 and DNAJB1. HSPA1B and HSPA6 are members of the HSP70 protein family, while DNAJB1 primarily interacts with HSP70 to stimulate its ATPase activity and negatively regulates the transcriptional activity of HSF1 induced by heat shock. Conclusion: HSP70 was the most significantly upregulated molecule in MM cells following bortezomib stimulation.

Advances in Biomimetic Nanotechnology for Triple-Negative Breast Cancer Therapy

2025-06-05T13:01:45+08:00

This article systematically reviews the application of biomimetic nanotechnology in targeted therapy for triple-negative breast cancer (TNBC). TNBC poses significant challenges for conventional treatments due to the lack of defined therapeutic targets, chemotherapy resistance, and a complex immunosuppressive microenvironment. Biomimetic nanotechnology, by mimicking the functional properties of biological structures (e.g., cell membranes, exosomes), has significantly enhanced drug delivery efficiency, targeting precision, and anti-tumor immune responses. This review focuses on the design strategies of biomimetic nanocarriers (including cell membrane-coated nanoparticles, engineered exosomes, and biomimetic synthetic materials) and their innovative applications in TNBC therapy: (1) Targeted delivery systems that overcome tumor barriers and reduce systemic toxicity; (2) Photothermal therapy combined with immunomodulation for precise treatment and immune activation; (3) Tumor microenvironment regulation (e.g., vascular normalization, pH neutralization, immunosuppression reversal). Studies demonstrate that biomimetic nanotechnology significantly improves TNBC treatment efficacy through multimodal synergistic mechanisms (e.g., chemo-photothermal-immunotherapy). However, challenges such as scalable production, long-term safety, and personalized adaptation remain for clinical translation. Future research should integrate artificial intelligence for optimized design and dynamic imaging technologies to advance biomimetic nanomedicines toward clinical applications.

Analysis of the Mediating Effect of Psychological Flexibility on Death Anxiety and Quality of Life in Cancer Patients

2025-06-05T13:01:49+08:00

Objective: To analyze the mediating effect of psychological flexibility between death anxiety and quality of life in cancer patients. Methods: A convenience sampling method was used to select cancer patients who received treatment at our hospital from January 2022 to January 2024, by the inclusion and exclusion criteria. General information, psychological flexibility, death anxiety, and quality of life scores were collected for analysis. Result: The psychological flexibility and quality of life scores of cancer patients with an annual family income ≤ 100,000 RMB were significantly lower than those of cancer patients with an annual family income > 100,000 RMB (P < 0.05), while the death anxiety scores were significantly lower for the former group as well (P < 0.05). Cancer patients staged as I-II had significantly higher psychological flexibility and quality of life scores than those staged as III-IV (P < 0.05), while their death anxiety scores were significantly lower (P < 0.05). Psychological flexibility in cancer patients was negatively correlated with death anxiety (r = -0.614, P < 0.05) and positively correlated with quality of life (r = 0.628, P < 0.05), while death anxiety was negatively correlated with quality of life (r = -0.112, P < 0.05). The direct effect of death anxiety on quality of life was -0.232, accounting for 58.32% of the total effect. The mediating effect of psychological flexibility between death anxiety and quality of life was -0.218, accounting for 41.83% of the total effect. Conclusion: Death anxiety can directly affect the quality of life of cancer patients, and it can also indirectly affect the quality of life through psychological flexibility. Clinicians should promptly address patients’ death anxiety and provide interventions to enhance psychological flexibility, thereby improving the quality of life.

Research Progress on Integrated Traditional Chinese and Western Medicine Therapy for Malignant Tumors

2025-06-05T13:01:43+08:00

The integration of Chinese and Western medicine in the treatment of malignant tumors is becoming increasingly widespread. By combining modern medical technology with traditional Chinese medicine, this approach enhances therapeutic efficacy while reducing side effects. This paper reviews the principles and mechanisms of integrated therapy and analyzes its clinical applications and advantages. Studies indicate that this approach is effective in treating common malignancies such as lung, stomach, and liver cancer, especially in slowing tumor progression, relieving symptoms, and improving patients’ quality of life. Chemotherapy combined with Chinese medicine has shown positive effects on survival rates and immune function. However, limitations remain, including insufficient clinical trial data and differences in efficacy across different cancer types, necessitating further high-quality studies. Overall, integrated Chinese and Western medicine offers advantages such as reduced side effects, improved survival rates, and enhanced immune function, providing a comprehensive treatment strategy and a theoretical foundation for its clinical application.

Observation on the Effect of Interventional Therapy Combined with Lenvatinib and Sintilimab in the Treatment of Advanced Liver Cancer

2025-05-29T15:41:43+08:00

Objective: To observe the control effect of interventional therapy combined with lenvatinib and sintilimab in patients with intermediate and advanced liver cancer. Methods: 82 patients with intermediate and advanced liver cancer who visited from January 2022 to January 2025 were selected as samples and randomly divided into two groups. Group A received interventional therapy combined with lenvatinib and sintilimab, while Group B received interventional therapy combined with lenvatinib. Disease remission rate, adverse reactions, liver function indicators, and tumor marker indicators were compared between the two groups. Results: The disease control rate (DCR) in Group A was higher than that in Group B (P < 0.05). There was no difference in adverse reaction rates between Group A and Group B (P > 0.05). Total bilirubin (TBil), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) levels in Group A were lower than those in Group B (P < 0.05). Carcinoembryonic antigen (CEA), alpha-fetoprotein (AFP), and alpha-L-fucosidase (AFU) levels in Group A were also lower than those in Group B (P < 0.05). Conclusion: Intermediate and advanced liver cancer patients receiving interventional therapy combined with lenvatinib and sintilimab showed reduced tumor marker levels, lessened liver function damage, and a high disease control rate and treatment safety.

Research Progress on Exosomes in the Diagnosis of Ovarian Cancer

2025-06-05T13:01:41+08:00

Ovarian cancer ranks as the deadliest malignancy among female reproductive system cancers, posing a significant threat to women’s health. Around seven out of ten patients are diagnosed only after reaching progressive disease phases, a phenomenon closely linked to three key factors: the disease’s hidden onset location, lack of early symptoms, and absence of reliable early diagnostic methods. Therefore, identifying early diagnostic biomarkers and therapeutic targets is critical. Exosomes participate in various phases of ovarian tumorigenesis, including transforming normal cells into cancerous cells, immune regulation, invasion, metastasis, drug resistance, and angiogenesis, making them promising biomarkers for early ovarian cancer detection. This review summarizes current research on exosomal long non-coding RNAs (lncRNAs), miRNAs, and related proteins in ovarian cancer diagnosis. Exosome-based biomarkers have shown potential advantages, including high sensitivity, specificity, stability, and non-invasive accessibility. The study concludes that while exosomes hold significant diagnostic potential for ovarian cancer, additional investigations are required to standardize detection methods, validate clinical applicability, and elucidate underlying molecular mechanisms.

Study on the Efficacy and Quality of Life Impact of Combination Adjuvant Chemotherapy with Epirubicin and Docetaxel for Breast Cancer Patients after Radical Mastectomy

2025-05-29T15:41:54+08:00

Objective: To explore and analyze the clinical effect of combination adjuvant chemotherapy with epirubicin and docetaxel for patients after radical mastectomy for breast cancer. Methods: This study enrolled 60 patients between May 2022 and December 2024, who were randomly allocated into two equal treatment groups (n = 30 each). The control group received standard chemotherapy, whereas the observation group was treated with a combined adjuvant regimen of epirubicin and docetaxel. Therapeutic outcomes were systematically compared between the groups. Results: The comparative analysis of chemotherapy regimens revealed significant intergroup differences in multiple outcome measures. The observation group demonstrated superior clinical efficacy (96.67% vs 80.00%, P < 0.05) alongside a more favorable safety profile (adverse reaction incidence: 3.33% vs 20.00%, P < 0.05). Metabolic assessments showed better glycemic control in the observation group, with both fasting and postprandial blood glucose levels being significantly lower than controls (P < 0.05), while maintaining comparable values to pretreatment baselines (P > 0.05). Furthermore, quality of life assessments indicated significantly better outcomes in the observation group compared to controls (P < 0.05). Conclusion: The combination of epirubicin and docetaxel as adjuvant chemotherapy for patients after radical mastectomy for breast cancer has significant clinical effects, can improve patients’ quality of life, and has high safety. It is worthy of adoption.

A Real-world Study on Adverse Events Related to Mirogabalin Based on the VigiAccess Database

2025-06-05T13:01:39+08:00

Objective: To utilize the VigiAccess database for data mining to analyze the characteristics of adverse reactions induced by mirogabalin, providing critical information for clinical medication use. Method: This study analyzed data from the VigiAccess database, filtering out adverse reaction reports where mirogabalin was identified as the Primary Suspect Drug (PS). Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayes Geometric Mean (EBGM) methods were employed as data mining algorithms for pharmacovigilance and adverse event monitoring. These methods identify potential drug-adverse event association signals by analyzing the relationship between drug use and adverse event reporting. ROR and PRR focus on calculating reporting ratios, while BCPNN and EBGM use neural networks and empirical Bayes models, respectively, to enhance the accuracy and reliability of signal detection. Results: A total of 734 adverse reaction reports associated with mirogabalin were obtained. The results showed that females reported the highest number of adverse reactions, accounting for 59.67%, while males accounted for 38.83%. In terms of age distribution, the highest number of reports came from individuals over 75 years old, accounting for 33.79%. Adverse reactions mainly involved the nervous system (33.45%), general diseases and reactions at the site of administration (11.62%), and gastrointestinal disorders (10.74%). The most common adverse reactions included dizziness (11.62%), somnolence (8.27%), renal dysfunction (2.90%), and edema (2.82%). Signal intensity analysis revealed that certain adverse reactions (such as renal dysfunction, rhabdomyolysis, and drug-induced liver injury) had significant signal strength, suggesting a strong association with mirogabalin. Conclusion: This study, through signal mining of the VigiAccess database, reveals the characteristics of mirogabalin’s adverse reactions in the real world, particularly in the nervous system and renal function. These findings provide important reference information for clinicians, aiding in the optimization of the safe use of mirogabalin. Future research should further validate the causal relationships of these signals and explore individualized treatment strategies to reduce the incidence of adverse reactions and improve patient outcomes.

Research Progress of Traditional Chinese Medicine Regulating PI3K/AKT/mTOR Signaling Pathway to Improve Myocardial Ischemia-Reperfusion Injury

2025-06-05T13:01:36+08:00

PI3K/AKT/mTOR signaling pathway is a key pathway of myocardial ischemia-reperfusion injury (MIRI). The mechanism of action is mainly oxidative stress, inflammatory response, calcium overload, ferroptosis, autophagy, and apoptosis. MIRI belongs to the category of chest obstruction in traditional Chinese medicine, and its etiology and pathogenesis are mainly “Yang Wei Yin Xian.” Traditional Chinese medicine has the effect of multi-target and multi-component effect, and has played a significant role in the treatment of MIRI in recent years. At present, the monomers of traditional Chinese medicine mainly include saponins, flavonoids, alkaloids, terpenoids, and phenols, and the compounds mainly include Zhigancao Decoction, Zhenyuan Capsule, Jiawei Shenqibai Powder, Qili Qiangxin Capsule, Tongmai Yangxin Pill, Zhilong Huoxue Tongyu Capsule, Guizhi Tongluo Tablets, etc. This paper reviews the research on the improvement of MIRI by regulating PI3K/ AKT/mTOR signaling pathway in recent years, and expounds the mechanism and advantages of traditional Chinese medicine in the treatment of MIRI.